LimFlow’s breakthrough system for treating chronic limb-threatening ischemia (CLTI) is the first of its kind approved by the FDA for this severe form of peripheral artery disease (PAD). For CLTI patients who have lost blood flow below their knee and have no other suitable endovascular or surgical treatment options available, the LimFlow System … [Read more...] about How LimFlow’s foot-saving system prevents amputations in patients with no other options
LimFlow
FDA approves LimFlow chronic limb-threatening ischemia treatment
LimFlow announced today that the FDA approved its LimFlow System for treating chronic limb-threatening ischemia (CLTI). Approval enables the treatment to help those with CLTI with no other suitable endovascular or surgical treatment options available. These patients can face major amputation as a result of their condition. France-based … [Read more...] about FDA approves LimFlow chronic limb-threatening ischemia treatment
Study backs LimFlow system for treating chronic limb-threatening ischemia
LimFlow announced that new study results demonstrated statistically significant survival with its chronic limb-threatening ischemia (CLTI) treatment. Paris-based LimFlow’s results came from its Promise II U.S. pivotal trial. They were published in today’s issue of the New England Journal of Medicine (NEJM). Data demonstrated 66% amputation-free … [Read more...] about Study backs LimFlow system for treating chronic limb-threatening ischemia
LimFlow raises $40M for chronic limb-threatening ischemia treatment
LimFlow announced that it closed an oversubscribed Series D financing round worth $40 million (€36 million). Paris-based LimFlow developed the LimFlow system for minimally invasive treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). The system uses a family of transcatheter products designed … [Read more...] about LimFlow raises $40M for chronic limb-threatening ischemia treatment
